

## SUPPLEMENTARY MATERIAL

## Periodic veganism in healthy individuals improves blood lipids, reduces low-grade inflammation, but impairs bone health: the FastBio study

Running headline: FastBio Biomarkers Study

Eleni M. Loizidou<sup>1,2</sup>, Petros Barbounakis<sup>3</sup>, Stavros Glentis<sup>1,4</sup>, Alexandros Dimopoulos<sup>1,5</sup>, Maria Anezaki<sup>1</sup>, Pavlos Rouskas<sup>6</sup>, Ioannis Kontoyiannis<sup>7</sup>, Nikolaos Demiris<sup>3</sup>, Konstantinos Rouskas<sup>1,8</sup>, Antigone S. Dimas<sup>1\*</sup>

<sup>9</sup> Institute for Bioinnovation, Biomedical Sciences Research Center 'Alexander Fleming', Fleming 34, 16672, Vari,  
<sup>10</sup> Greece

<sup>2</sup> biobank.cy Center of Excellence in Biobanking and Biomedical Research, University of Cyprus, Cyprus

12 3 Department of Statistics, Athens University of Economics and Business, Athens, Greece

**13**   <sup>4</sup>Pediatric Hematology/Oncology Unit (POHemU), First Department of Pediatrics, University of Athens, Aghia  
**14**   Sophia Children's Hospital, Levadias 8, 11527, Athens, Greece

<sup>15</sup> <sup>5</sup> Hellenic Naval Academy, Hatzikyriakou Avenue, Pireaus 185 39, Greece

<sup>16</sup> <sup>6</sup> 1st Department of Cardiology, AHEPA University Hospital, Aristotle University, Thessaloniki, Greece

<sup>7</sup> Statistical Laboratory, Centre for Mathematical Sciences, University of Cambridge, United Kingdom

<sup>18</sup> Institute of Applied Biosciences, Centre for Research & Technology Hellas, Thessaloniki, Greece

## 35      SUPPLEMENTARY TEXT

## 36 Text S1. Inclusion and exclusion criteria for FastBio study participants

### 37 Inclusion criteria:

- 38 • Healthy female and male subjects 18 – 75 years of age at the time of enrollment. One  
39 participant turned 76 between time of enrollment and first sampling timepoint (T1).  
40 • Able to provide signed and dated informed consent. Willing to provide blood samples.  
41 • Periodic vegan (PV) individuals who have followed the specific dietary regimen for at  
42 least ten years.  
43 • Non-vegan (NV) individuals who do not follow any kind of specific diet including periodic  
44 veganism, veganism, vegetarianism, caloric restriction, intermittent fasting etc.

#### 45 Exclusion criteria:

- 46       • Use of antibiotic, antifungal, antiviral or antiparasitic drugs six months prior to T1.  
47       • Acute disease, defined as the presence of a moderate or severe illness with or without fever,  
48           at sampling timepoints.  
49       • Alcohol or drug abuse two years prior to T1.  
50       • Participants who are normally PV, but had to alter their diet for a specific reason (e.g.  
51           pregnancy).

52

## 53 Text S2. HOMA indices

54 Prior to calculating HOMA indices, we inspected our data for glucose levels < 2.5mmol/L. No  
55 individuals were excluded based on this threshold. We calculated HOMA indices as follows [1,  
56 2]:

$$(a) HOMA - B = (360 * \text{Insulin}) / (\text{Glucose} - 63)$$

58

(b)  $HOMA - IR = (\text{Insulin} * \text{Glucose})/405$

60

## 61 Text S3. BMI and age categories

Participants were grouped into four age categories based on representative classifications in the literature [3-5]: 19-40, 41-50, 51-60 and 61-76 years old (Supplementary Table S1) and four BMI categories as indicated by the World Health Organization (WHO) [6]: < 18.5 kg/m<sup>2</sup> underweight; 18.5 kg/m<sup>2</sup> ≤ BMI < 25 kg/m<sup>2</sup> normal weight; 25 kg/m<sup>2</sup> ≤ BMI < 30 kg/m<sup>2</sup>, overweight; and ≥ 30 kg/m<sup>2</sup> obese (Supplementary Table S1).

67

68

69

70

71 **Text S4. Model adjustments**

72 Medications accounted for included drugs for blood lipids, blood pressure, blood glucose levels,  
73 osteoporosis, thyroid function, and anticoagulants. All models were run with: (a) medication use  
74 as a single, binary covariate (Yes/No), and (b) each medication type as a separate covariate with  
75 no differences in overall findings and reported estimates and CIs are using (b).

76 In addition to the model adjustments described in the main text, we also adjusted for smoking and  
77 alcohol consumption with no impact on results and were therefore excluded from the analysis.  
78 Self-reported levels of physical activity, which did not differ substantially between dietary groups  
79 in each timepoint and for each dietary group across timepoints, were not included in the models.

80 **Text S5. Self-reported use of dietary supplements**

81 Self-reported use of dietary supplements for FastBio participants was as follows:

82 PV group: Mg (1 participant), Fe (2 participants), Vitamin B (1 participant) Calcium (3  
83 participants), Vitamin B and Calcium (1 participant), Vitamin D (1 participant), amino acid  
84 supplement (1 participant)

85 NV group: Calcium (1 participant), Vitamin D (1 participant).

86

87


88 **SUPPLEMENTARY FIGURES**

89 **Fig. S1. Indicative calendar showing days of abstinence from meat, fish, dairy products and**  
 90 **eggs (in grey) for PV individuals.** Abstinence ranges from ~180-200 days annually, with four  
 91 extended periods throughout the year and abstinence on Wednesdays and Fridays of each week.  
 92 When not abstaining, PV individuals follow an omnivorous diet.

Day/Month		Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
1	M												
2	T												
3	W												
4	T												
5	F												
6	S												
7	S												
8	M												
9	T												
10	W												
11	T												
12	F												
13	S												
14	S												
15	M												
16	T												
17	W												
18	T												
19	F												
20	S												
21	S												
22	M												
23	T												
24	W												
25	T												
26	F												
27	S												
28	S												
29	M		---										
30	T		---										
31	W		---		---		---		---		---		---

93

**Fig. S2.** The FastBio study includes comparisons of measured traits: (A) across timepoints for each dietary group, and (B) between dietary groups for each timepoint. PV: periodic vegan, NV: non-vegan.



## SUPPLEMENTARY TABLES

**Table S1. Blood biomarkers and CBC traits measured in PV and NV dietary groups, at two timepoints.**

Measured traits	Mean ± sd				Units	Normal range†
	T1		T2			
Blood biomarkers	PV <sub>(n=200)</sub>	NV <sub>(n=211)</sub>	PV <sub>(n=192)</sub>	NV <sub>(n=198)</sub>		
Total cholesterol	5.1±0.9	4.9±0.8	4.7±0.9	5.0±0.9	mmol/l	< 5.2
LDL	3.4±0.8	3.3±0.8	3.1±0.8	3.3±0.9	mmol/l	< 3.4
HDL	1.6±0.4	1.6±0.4	1.5±0.4	1.5±0.4	mmol/l	0.9-1.6
Triglycerides	2.7±1.3	2.5±1.4	2.8±1.3	2.6±1.2	mmol/l	< 3.9
Glucose	2.5±0.3	2.4±0.3	2.5±0.3	2.5±0.3	mmol/l	1.9-3.0
Insulin	9.8±9.0	9.4±13.4	10.4±11.0	9.4±9.3	mU/L	3.0-25.0
HbA1c	5.3±0.5	5.2±0.5	5.3±0.4	5.2±0.5	%	4.5-6.2
Urea	32±9.1	30±7.8	26±7.3	30±7.4	mg/dl	10-50
Uric acid	5.1±1.3	4.8±1.3	5.0±1.2	4.8±1.3	mg/dl	2.4-5.7
Creatinine	0.8±0.2	0.8±0.2	0.7±0.2	0.8±0.1	mg/dl	0.5-0.9
AST	19.1±7.7	18.5±6.0	20.0±7.0	18.7±4.9	U/I	10-32
ALT	20.8±12.5	20.5±12.2	19.1±11.5	19.4±9.0	U/I	10-33
γ-GT	19.3±15.9	18.8±17.3	16.1±11.0	17.4±15.9	U/I	5-36
ALP	66.0±17.3	60.0±16.4	68.0±17.0	60.0±15.8	U/I	35-104
TSH	2.0±1.3	1.8±1.0	2.0±1.1	1.9±1.1	mIU/L	0.4-4.9
CRP	2.6±2.7	2.2±2.4	2.2±2.3	2.4±3.6	mg/L	0-5
<b>HOMA</b>						
HOMA-B	107.6±71.8	106.6±88.9	117.3±112.9	104.3±85.5	---	---
HOMA-IR	2.4±2.6	2.4±4.7	2.5±2.9	2.3±2.4	---	---
<b>CBC</b>						
WBC	6.1±1.5	6.4±1.7	5.7±1.4	6.1±1.6	K/µl	4.0-11.0
Lymphocytes	2.0±0.6	2.0±0.6	1.9±0.6	2.0±0.6	x10 <sup>3</sup> /µl	1.5-4.0
Lymphocyte %	33.0±6.5	32.0±7.1	34.0±7.1	33.0±7.5	%	20-40
Eosinophils	0.2±0.1	0.2±0.2	0.2±0.1	0.2±0.1	x10 <sup>3</sup> /µl	< 0.4
Eosonophil %	2.5±1.6	3.1±2.3	2.8±2.1	3.1±2.1	%	1 - 6
Monocytes	0.4±0.1	0.4±0.1	0.4±0.1	0.4±0.1	x10 <sup>3</sup> /µl	0.1-0.9
Monocyte %	6.7±1.7	6.8±1.7	7.5±1.7	7.3±1.6	%	2-10
Basophils	0.003±0.02	0.003±0.02	0.003±0.02	0.003±0.02	x10 <sup>3</sup> /µl	< 0.1
Basophil %	0.03±0.2	0.04±0.2	0.04±0.2	0.03±0.2	%	0.3 - 1.0
Neutrophils	3.6±1.1	3.8±1.3	3.2±1.0	3.5±1.2	x10 <sup>3</sup> /µl	2.0-7.7
Neutrophil %	58.1±6.9	58.5±7.7	55.5±7.7	56.3±8.1	%	40 - 75
RBC	4.9±0.5	4.9±0.5	4.9±0.5	5.0±0.5	M/ml	3.8-5.8
Hemoglobin	14.2±1.4	14.2±1.5	14.0±1.3	14.1±1.4	g/dl	11.5-16.5
Hematocrit	42.6±3.5	42.3±3.6	42.2±3.4	42.4±3.5	%	37-47
MCH	29.3±2.4	29.1±3.0	28.8±2.4	28.6±3.0	pg	26.0 - 32.0
MCHC	33.4±0.9	33.4±1.0	33.2±1.0	33.3±1.0	g/dL	30-36
MCV	87.8±6.4	87.0±7.9	86.8±6.4	85.7±7.8	fL	79.0 - 98.0
RDW CV	13.6±0.9	13.6±1.2	13.5±1.0	13.6±1.2	%	11.0 - 16.0
RDW SD	43.0±3.0	42.8±3.4	42.5±3.2	42.1±3.3	fL	38-43
Platelets	246.0±51.1	236.8±48.3	236.3±50.0	235.1±50.0	K/µl	150.0-400.0
PDW*	12.7±2.8	12.4±3.7	12.9±1.9	13.0±1.9	%	9.0-17.0
MPV*	10.5±1.9	10.2±2.8	10.6±0.9	10.7±0.8	µm	6-11
P-LCR*	30.6±8.8	30.2±10.4	30.2±7.3	30.5±6.9	%	13.0 - 43.0

† = IBH (Interbalkan Hospital) blood biomarker normal range, \* = Paired data available for 190 PV and 193 NV individuals

HOMA = Homeostasis Model Assessment; WBC = White Blood Cells; RBC = Red Blood Cells; MCH = Mean Corpuscular Hemoglobin; MCHC = Mean Corpuscular Hemoglobin Concentration; RDW CV = Red Cell Distribution Width Coefficient of Variation; Red Cell Distribution Width Standard Deviation = RDW SD; PDW = Platelet Distribution Width; MPV = Mean Platelet Volume; P-LCR = Platelet-Large Cell Ratio

**Table S2. Participant characteristics at timepoint 1 (T1) and timepoint 2 (T2).**

Timepoint 1	Subgroups	PV (n = 200)	NV (n = 211)	Total (n = 411)
<b>Age (years) (mean±sd)</b>		51.5±13.5	45±13.07	48.1±13.6
	Group 1: 19-40 (%)	35 (17.5)	82 (38.9)	28.5 %
	Group 2: 41-50 (%)	48 (24)	43 (20.4)	22.1 %
	Group 3: 51-60 (%)	52 (26)	55 (26)	26%
	Group 4: 61-76 (%)	65 (32.5)	31 (14.7)	23.4%
<b>Sex (%)</b>	Female	108 (54)	116 (55)	54.5%
	Male	92 (0.5)	95 (45)	45.5%
<b>Weight (kg) (mean±sd)</b>	---	80±15.7	76±15.8	78±15.8
<b>BMI (kg/m<sup>2</sup>) (mean±sd)</b>		28.4±4.6	26.2±4.4	27.3±4.6
	Group 1: < 18.5 (%)	1 (0.5)	6 (2.8)	1.7%
	Group 2: 18.5-25 (%)	39 (19.5)	77 (36.5)	28.2%
	Group 3: 25-30 (%)	99 (49.5)	89 (42.2)	45.7%
	Group 4: ≥ 30 (%)	61 (30.5)	39 (18.5)	24.3%
<b>Smoking (%)</b>	Non-smoker (%)	187 (93.5)	141 (66.8)	79.8 %
	Smoker (%)	13 (6.5)	70 (33.2)	20.2 %
<b>Blood pressure (mmHg) (mean±sd)</b>				
	SBP	127±19.0	121±19.7	124±19.4
	DBP	80±10.8	78±11.8	79±11.3

SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure

Timepoint 2	Subgroups	PV (n = 192)	NV (n = 198)	Total (n = 390)
<b>Age (years) (mean±sd)</b>		51.5 ± 13.4	45.3 ± 13.1	48.3±13.6
	Group 1: 19-40 (%)	34 (17.7)	76 (38.4)	28.2 %
	Group 2: 41-50 (%)	45 (23.4)	39 (19.7)	21.5 %
	Group 3: 51-60 (%)	50 (26)	53 (26.8)	26.4%
	Group 4: 61-76 (%)	63 (32.8)	30 (15.1)	23.8 %
<b>Sex (%)</b>	Female	103 (53.6)	108 (54.5)	54.1 %
	Male	89 (46.4)	90 (45.5)	45.9 %
<b>Weight (kg) (mean±sd)</b>	---	79±15.5	77±15.6	78±15.5
<b>BMI (kg/m<sup>2</sup>) (mean±sd)</b>		28.3 ± 4.6	26.6 ± 4.4	27.4 ± 4.6
	Group 1: < 18.5 (%)	1 (0.5)	5 (2.5)	1.5 %
	Group 2: 18.5-25 (%)	41 (21.4)	65 (32.8)	27.2 %
	Group 3: 25-30 (%)	91 (47.4)	87 (43.9)	45.6 %
	Group 4: ≥ 30 (%)	59 (30.7)	41 (20.7)	25.6 %
<b>Smoking status (%)</b>	Non-smoker (%)	179 (93.2)	137 (69.2)	81 %
	Smoker (%)	13 (6.8)	61 (30.8)	19 %
<b>Blood pressure (mmHg) (mean±sd)</b>	SBP	125±17.3	120±18.7	112.5±18.0
	DBP	78±10.6	78±12.2	78±11.4

SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure

**Table S3. FastBio participant medication use.**

	PV	NV	Total (n)
<b>Blood lipids</b>	27	13	40
<b>Blood glucose levels</b>	7	2	9
<b>Osteoporosis</b>	6	3	9
<b>Thyroid function</b>	23	26	49
<b>Blood pressure</b>	36	17	53
<b>Other</b>	12	21	33

**Table S4. Sensitivity analysis on the changes in blood biomarkers for PV and NV dietary groups across timepoints.** Comparisons are reported in reference to T2. Positive effect estimates indicate an increase in blood biomarkers at T2, negative effect estimates indicate a decrease.

Measured traits	Units	PV				NV			
		PV Estimate	P-value	Lower CI	Upper CI	NV Estimate	P-value	Lower CI	Upper CI
Total cholesterol	mmol/L	-0.3	0.0001***	-0.5	-0.2	0.04	0.6	-0.1	0.2
LDL cholesterol	mmol/L	-0.3	0.0003**	-0.4	-0.1	0.04	0.6	-0.1	0.2
HDL cholesterol	mmol/L	-0.06	0.07	-0.1	5.7e-3	-4.9e-3	0.9	-0.07	0.06
Triglycerides	mmol/L	1.3e-3	0.3	-9.05e-4	3.4e-3	5.2e-4	0.7	-1.8e-3	2.6e-3
Glucose	mmol/L	0.0002	0.7	-0.001	0.001	0.0006	0.2	-0.0003	0.002
Insulin	mU/L	0.07	0.1	-0.02	0.2	0.04	0.4	-0.06	0.1
HbA1c	%	-0.04	0.4	-0.1	0.04	-0.01	0.7	-0.09	0.06
Urea	mg/dL	-5.8	1.6e-13***	-7.3	-4.3	0.3	0.7	-1.2	1.7
Uric acid	mg/dL	-0.05	0.6	-0.2	0.2	-0.02	0.9	-0.2	1.7
Creatinine	mg/dL	-0.06	9.7e-05***	-0.09	-0.03	-0.02	0.2	-0.05	0.008
AST	U/L	0.04	0.2	-0.01	0.09	0.02	0.5	-0.03	6.9
ALT	U/L	-0.09	0.02*	-0.2	-0.01	-0.04	0.3	-0.1	0.04
γ-GT	U/L	-0.1	0.009*	-0.2	-0.03	-0.09	0.05*	-0.2	0.002
ALP	U/L	2.6	0.1	-0.6	5.7	0.5	0.8	-2.6	3.6
TSH	mIU/L	0.05	0.7	-0.2	0.3	0.1	0.2	-0.08	0.4
CRP	mg/L	-1.4	0.03*	-2.8	-0.1	-0.5	0.5	-1.8	0.8

**P-value:** \* ≤ 0.05, \*\* ≤ 0.001, \*\*\* ≤ 0.0001

**Table S5. Mean CRP for individuals with levels > 5mg/L in T1 and T2.**

		Mean ± sd	
		T1	T2
<b>PV (N<sub>T1</sub>=19/N<sub>T2</sub>=11)</b>		1.0 ± 2.9	0.6 ± 2.3
<b>NV (N<sub>T1</sub>=18/N<sub>T2</sub>=15)</b>		0.9 ± 2.8	0.8 ± 2.7

**Table S6. Sensitivity analysis on the changes in CBC traits for PV and NV dietary groups across timepoints.** Comparisons are reported with reference to T2. Positive effect estimates indicate an increase in CBC traits at T2, negative effect estimates indicate a decrease.

Measured traits	Units	PV			NV				
		PV Estimate	P-value	Lower CI	Upper CI	NV Estimate	P-value	Lower CI	Upper CI
WBC	K/µL	-0.05	0.002*	-0.8	-0.2	-0.3	0.03*	-0.6	-0.02
Lymphocytes	x10 <sup>3</sup> /µL	-0.06	0.3	-0.2	0.06	-0.02	0.8	-0.1	0.1
Lymphocyte %	%	1.6	0.03*	0.2	3.0	1.5	0.03*	0.1	2.9
Eosinophils	x10 <sup>3</sup> /µL	0.007	0.6	-0.02	0.04	-0.01	0.3	-0.04	0.01
Eosonophil %	%	0.3	0.2	-0.1	0.7	-0.04	0.9	-0.4	0.4
Monocytes	x10 <sup>3</sup> /µL	0.02	0.2	-0.009	0.04	0.02	0.07	-0.002	0.05
Monocyte %	%	0.7	1.05e-5***	0.4	1.0	0.6	3.5e-4**	0.3	0.9
Basophils	x10 <sup>3</sup> /µL	7.8e-4	0.7	-0.003	0.004	-1.8e-4	0.9	-0.004	0.003
Basophil %	%	0.01	0.5	-0.02	0.05	-0.01	0.5	-0.05	0.03
Neutrophils	x10 <sup>3</sup> /µL	-0.4	5e-5***	-0.6	-0.2	-0.3	0.01*	-0.5	-0.06
Neutrophil %	%	-2.6	9e-4**	-4.1	-1.07	-2.1	0.008*	-3.6	-0.6
RBC	M/mL	-0.03	0.5	-0.2	0.06	0.003	0.9	-0.08	0.09
Hemoglobin	g/dL	-0.2	0.07	-0.4	0.02	0.06	0.6	-0.1	0.3
Hematocrit	%	-0.4	0.2	-0.9	0.2	0.2	0.4	-0.3	0.7
MCH	pg	-0.3	0.3	-0.8	0.2	0.02	0.9	-0.5	0.5
MCHC	g/dL	-0.1	0.1	-0.3	0.04	-0.01	0.9	-0.2	0.2
MCV	fL	-0.4	0.5	-1.7	0.9	0.1	0.9	-1.2	1.4
RDW CV	%	-0.1	0.2	-0.3	0.07	-0.2	0.01*	-0.4	-0.05
RDW SD	fL	-0.4	0.2	-1.0	0.2	-0.4	0.2	-1.0	0.2
Platelets	K/µL	-9.4	0.05	-18.8	0.1	-2.8	0.6	-12.1	6.6
PDW	%	0.2	0.5	-0.3	0.7	0.5	0.05	0.0003	1.08
MPV	µm	0.1	0.6	-0.3	0.5	0.4	0.02*	0.05	0.8
P-LCR	%	-0.5	0.6	-2.2	1.2	0.1	0.9	-1.6	1.8

**P-value:** \* ≤ 0.05, \*\* ≤ 0.001, \*\*\* ≤ 0.0001

WBC = White Blood Cells; RBC = Red Blood Cells; MCH = Mean Corpuscular Hemoglobin; MCHC = Mean Corpuscular Hemoglobin Concentration; RDW CV = Red Cell Distribution Width Coefficient Of Variation; Red Cell Distribution Width Standard Deviation = RDW SD; PDW = Platelet Distribution Width; MPV = Mean Platelet Volume; P-LCR = Platelet-Large Cell Ratio

**Table S7. Changes in anthropometric and blood pressure traits for PV and NV dietary groups across timepoints.** Comparisons are reported with reference to T2. Positive effect estimates indicate an increase in anthropometric and blood pressure traits at T2, negative effect estimates indicate a decrease.

		PV				NV			
Measured traits	Units	PV Estimate	P-value	Lower CI	Upper CI	NV Estimate	P-value	Lower CI	Upper CI
Weight	kg	-0.2	0.5	-0.7	0.4	<b>1.0</b>	<b>0.0002**</b>	<b>0.5</b>	<b>1.5</b>
BMI	kg/m <sup>2</sup>	-0.02	0.5	-0.07	0.04	0.05	0.07	-0.004	0.002
SBP	mmHg	-1.9	0.06	-3.9	0.09	<b>-2.2</b>	<b>0.03*</b>	<b>-4.2</b>	<b>-0.2</b>
DBP	mmHg	<b>-2.5</b>	<b>0.0002**</b>	<b>-3.7</b>	<b>-1.2</b>	<b>-2.2</b>	<b>0.0006**</b>	<b>-3.5</b>	<b>-1.0</b>

**P-value:** \* ≤ 0.05, \*\* ≤ 0.001, \*\*\* ≤ 0.0001

SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure

**Table S8. Sensitivity analysis on the differences in blood biomarkers between dietary groups for each timepoint.** Comparisons are reported with reference to the PV group. Positive effect estimates indicate higher levels of blood biomarkers in the PV compared to the NV group, negative effect estimates indicate lower levels.

T1						T2			
Measured traits	Units	T1 Estimate	P-value	Lower CI	Upper CI	T2 Estimate	P-value	Lower CI	Upper CI
Total cholesterol	mmol/L	0.04	0.6	-0.1	0.2	<b>-0.3</b>	<b>3.4e-05***</b>	<b>-0.5</b>	<b>-0.2</b>
LDL	mmol/L	-1.3e-3	1.0	-0.2	0.1	<b>-0.3</b>	<b>1.01e-05***</b>	<b>-0.5</b>	<b>-0.2</b>
HDL	mmol/L	0.05	0.2	-0.02	0.1	-7.8e-3	0.8	-0.08	0.06
Triglycerides	mmol/L	-1.3e-4	0.9	-0.002	0.002	5.2e-4	0.7	-1.8e-3	2.6e-3
Glucose	mmol/L	-2.07e-4	0.4	-7.8e-4	0.03	<b>-0.001</b>	<b>0.05*</b>	<b>-0.002</b>	<b>1e-5</b>
Insulin	mU/L	0.01	0.9	-0.1	0.1	0.03	0.4	-0.07	0.1
HbA1c	%	-0.02	0.7	-0.1	0.07	-0.05	0.2	-0.1	0.03
Urea	mg/dL	0.7	0.4	-1.0	2.4	<b>-4.9</b>	<b>5.5e-10***</b>	<b>-6.4</b>	<b>-3.4</b>
Uric acid	mg/dL	0.1	0.2	-0.06	0.3	0.1	0.3	-0.09	0.3
Creatinine	mg/dL	-0.02	0.3	-0.05	0.06	<b>-0.05</b>	<b>0.0006**</b>	<b>-0.08</b>	<b>-0.02</b>
AST	U/L	0.005	0.9	-0.05	0.06	0.03	0.3	-0.02	0.08
ALT	U/L	-0.01	0.8	-0.1	0.07	-0.07	0.09	-0.2	0.01
γ-GT	U/L	-0.06	0.3	-0.2	0.05	<b>-0.1</b>	<b>0.03*</b>	<b>-0.2</b>	<b>-0.01</b>
ALP	U/L	<b>3.6</b>	<b>0.04*</b>	<b>0.2</b>	<b>6.9</b>	<b>5.8</b>	<b>0.0004**</b>	<b>2.6</b>	<b>8.9</b>
TSH	mIU/L	<b>0.3</b>	<b>0.03*</b>	<b>0.03</b>	<b>0.5</b>	0.2	0.1	-0.05	0.4
CRP	mg/L	0.2	0.8	-1.0	1.6	-0.6	0.4	-1.9	0.7

**P-value:** \* ≤ 0.05, \*\* ≤ 0.001, \*\*\* ≤ 0.0001

**Table S9. Sensitivity analysis on the differences in CBC traits between dietary groups for each timepoint.** Comparisons are reported with reference to the PV group. Positive effect estimates indicate higher levels of CBC traits for the PV compared to the NV group, negative effect estimates indicate lower levels.

Measured traits	Units	T1				T2			
		Estimate	P-value	Lower CI	Upper CI	Estimate	P-value	Lower CI	Upper CI
WBC	K/ $\mu$ L	-0.4	0.03*	-0.7	-0.03	-0.5	0.002*	-0.8	-0.2
Lymphocytes	x10 <sup>3</sup> / $\mu$ L	-0.04	0.5	-0.2	0.08	-0.08	0.2	-0.2	0.04
Lymphocyte %	%	1.0	0.2	-0.5	2.4	1.04	0.2	-0.4	2.5
Eosinophils	x10 <sup>3</sup> / $\mu$ L	-0.04	0.02*	-0.07	-0.008	-0.02	0.2	-0.05	0.009
Eosonophil %	%	-0.5	0.02*	-0.9	-0.07	-0.2	0.3	-0.6	0.2
Monocytes	x10 <sup>3</sup> / $\mu$ L	-0.02	0.1	-0.05	0.007	-0.02	0.06	-0.05	0.001
Monocyte %	%	-0.009	1.0	-0.3	0.3	0.1	0.4	-0.2	0.5
Basophils	x10 <sup>3</sup> / $\mu$ L	-0.001	0.5	-0.005	0.003	-6.9e-4	0.7	-0.004	0.003
Basophil %	%	-0.02	0.4	-0.06	0.02	0.006	0.8	-0.03	0.04
Neutrophils	x10 <sup>3</sup> / $\mu$ L	-0.3	0.04*	-0.5	-0.01	-0.4	0.002*	-0.6	-0.1
Neutrophil %	%	-0.4	0.6	-2.0	1.1	-1.0	0.2	-2.5	0.6
RBC	M/mL	-0.02	0.5	-0.1	0.07	-0.06	0.2	-0.1	0.03
Hemoglobin	g/dL	0.07	0.5	-0.1	0.3	-0.2	0.09	-0.4	0.03
Hematocrit	%	0.2	0.6	-0.4	0.7	-0.4	0.1	-1.0	0.1
MCH	pg	0.2	0.5	-0.4	0.8	-0.06	0.8	-0.6	0.4
MCHC	g/dL	0.04	0.6	-0.1	0.2	-0.08	0.4	-0.3	0.1
MCV	fL	0.5	0.5	-1.0	2.07	0.03	1.0	-1.3	1.4
RDW CV	%	-0.2	0.08	-0.4	0.03	-0.08	0.4	-0.3	0.1
RDW SD	fL	-0.3	0.4	-0.9	0.4	-0.2	0.5	-0.8	0.4
Platelets	K/ $\mu$ L	7.7	0.1	-2.3	17.7	0.9	0.9	-8.9	10.6
PDW	%	0.3	0.5	-0.4	1.0	-0.008	1.0	-0.6	0.5
MPV	$\mu$ m	0.2	0.4	-0.3	0.7	-0.05	0.8	-0.4	0.3
P-LCR	%	0.3	0.8	-1.8	2.3	-0.1	0.9	-1.9	3.7

**P-value:** \* ≤ 0.05, \*\* ≤ 0.001, \*\*\* ≤ 0.0001

WBC = White Blood Cells; RBC = Red Blood Cells; MCH = Mean Corpuscular Hemoglobin; MCHC = Mean Corpuscular Hemoglobin Concentration; RDW CV = Red Cell Distribution Width Coefficient Of Variation; Red Cell Distribution Width Standard Deviation = RDW SD; PDW = Platelet Distribution Width; MPV = Mean Platelet Volume; P-LCR = Platelet-Large Cell Ratio

**Table S10. Differences in anthropometric and blood pressure traits between dietary groups for each timepoint.** Comparisons are reported with reference to the PV group. Positive effect estimates indicate higher levels of anthropometric and blood pressure traits in the PV compared to the NV group, negative effect estimates indicate lower levels.

		T1					T2			
Measured traits	Units	T1 Estimate	P-value	Lower CI	Upper CI		T2 Estimate	P-value	Lower CI	Upper CI
Weight	kg	2.1	0.1	-0.5	4.7		1.04	0.4	-1.6	3.7
BMI	kg/m <sup>2</sup>	<b>0.2</b>	<b>0.003*</b>	<b>0.08</b>	<b>0.4</b>		0.1	0.06	-0.002	0.3
SBP	mmHg	0.4	0.8	-2.9	3.6		-0.8	0.6	-4.0	2.4
DBP	mmHg	0.02	1.0	-2.0	2.0		-1.04	0.3	-3.05	1.0

**P-value:** \* ≤ 0.05, \*\* ≤ 0.001, \*\*\* ≤ 0.0001

SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure

## REFERENCES

1. Yoo, T.K., et al., *Association between physical activity and insulin resistance using the homeostatic model assessment for insulin resistance independent of waist circumference*. Sci Rep, 2022. **12**(1): p. 6002.
2. Ito, R., et al., *Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naive Patients with Type 2 Diabetes*. Drugs R D, 2015. **15**(3): p. 245-51.
3. Geifman, N., R. Cohen, and E. Rubin, *Redefining meaningful age groups in the context of disease*. Age (Dordr), 2013. **35**(6): p. 2357-66.
4. Franssen, T., et al., *Age differences in demographic, social and health-related factors associated with loneliness across the adult life span (19–65 years): a cross-sectional study in the Netherlands*. BMC Public Health, 2020. **20**(1): p. 1118.
5. Swift, H.J., et al., *Categorization by Age*, in *Encyclopedia of Evolutionary Psychological Science*, T.K. Shackelford and V.A. Weekes-Shackelford, Editors. 2018, Springer International Publishing: Cham. p. 1-10.
6. Stenholm, S., et al., *Body mass index as a predictor of healthy and disease-free life expectancy between ages 50 and 75: a multicohort study*. International Journal of Obesity, 2017. **41**(5): p. 769-775.